Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
ARMC5-CUL3 E3 ligase targets full-length SREBF in adrenocortical tumors
Yosuke Okuno, Atsunori Fukuhara, Michio Otsuki, Iichiro Shimomura
Yosuke Okuno, Atsunori Fukuhara, Michio Otsuki, Iichiro Shimomura
View: Text | PDF
Research Article Endocrinology

ARMC5-CUL3 E3 ligase targets full-length SREBF in adrenocortical tumors

  • Text
  • PDF
Abstract

Inactivating mutations of ARMC5 are responsible for the development of bilateral macronodular adrenal hyperplasia (BMAH). Although ARMC5 inhibits adrenocortical tumor growth and is considered a tumor-suppressor gene, its molecular function is poorly understood. In this study, through biochemical purification using SREBF (SREBP) as bait, we identified the interaction between SREBF and ARMC5 through its Armadillo repeat. We also found that ARMC5 interacted with CUL3 through its BTB domain and underwent self-ubiquitination. ARMC5 colocalized with SREBF1 in the cytosol and induced proteasome-dependent degradation of full-length SREBF through ubiquitination. Introduction of missense mutations in Armadillo repeat of ARMC5 attenuated the interaction between SREBF, and introduction of mutations found in BMAH completely abolished its ability to degrade full-length SREBF. In H295R adrenocortical cells, silencing of ARMC5 increased full-length SREBFs and upregulated SREBF2 target genes. siARMC5-mediated cell growth was abrogated by simultaneous knockdown of SREBF2 in H295R cells. Our results demonstrate that ARMC5 was a substrate adaptor protein between full-length SREBF and CUL3-based E3 ligase, and they suggest the involvement of the SREBF pathway in the development of BMAH.

Authors

Yosuke Okuno, Atsunori Fukuhara, Michio Otsuki, Iichiro Shimomura

×

Figure 3

ARMC5 interacted with CUL3 and underwent self-ubiquitination.

Options: View larger image (or click on image) Download as PowerPoint
ARMC5 interacted with CUL3 and underwent self-ubiquitination.
(A) Wester...
(A) Western blotting of lysates from the differentiated 3T3-L1–TetON-FLAG (FLAG), 3T3-L1–TetON-FLAG-Armc5 (WT), or 3T3-L1–TetON-FLAG-Armc5ΔBTB (ΔBTB) cells treated with or without 10 μg/mL doxycycline for 30 hours with an anti-FLAG antibody. (B) Venn diagrams representing the number of identified proteins by LC-MS/MS of the sample immunoprecipitated with anti-FLAG antibody from the nuclear extracts of the differentiated 3T3-L1–TetON-FLAG (FLAG), 3T3-L1–TetON-FLAG-Armc5 (WT), or 3T3-L1–TetON-FLAG-Armc5ΔBTB (ΔBTB) cells treated with 10 μg/mL doxycycline. (C) Western blotting of lysates (input) or samples immunoprecipitated with high-salt TNE buffer and anti-FLAG antibody (IP) from the HEK293T cells transfected with pcDNA3.1-FLAG, pcDNA3.1-FLAG-mArmc5 (WT), or pcDNA3.1-FLAG-mArmc5ΔBTB (ΔBTB) with the indicated antibodies. (D) Western blotting of lysates from the HEK293T cells transfected with pcDNA3.1-FLAG-mArmc5 for 24 hours, followed by treatment with 10 μM MG132 for the indicated times with an anti-FLAG antibody. (E and F) Cell-based ubiquitination assays of the HEK293T cells (E) or H295R cells (F) transfected with pcDNA3.1-FLAG or pcDNA3.1-FLAG-mArmc5, followed by treatment with or without MG132, using the indicated antibody. See complete unedited blots in the supplemental material.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts